Suzhou Zion Pharma Technology Co. Ltd. has identified GTPase KRAS G12D or G13D mutant and/or KRAS inhibitors reported to be useful for the treatment of cancer.
Investigation of Racial Disparities in Early Supportive Medication Use and End-of-Life Care Among Medicare Beneficiaries With Stage IV Breast Cancer ...
Suzhou Zion Pharma Technology Co Ltd. has identified KRAS inhibitors, in particular GTPase KRAS G12D mutant and/or G13D mutant, reported to be useful for the treatment of cancer. Suzhou Zion Pharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback